Free Trial

Bristol Myers Squibb (BMY) Competitors

Bristol Myers Squibb logo
$47.64 +0.13 (+0.27%)
Closing price 03:59 PM Eastern
Extended Trading
$47.58 -0.05 (-0.12%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BMY vs. AMGN, EXEL, GILD, MRNA, VRTX, ABBV, JNJ, LLY, MRK, and PFE

Should you be buying Bristol Myers Squibb stock or one of its competitors? The main competitors of Bristol Myers Squibb include Amgen (AMGN), Exelixis (EXEL), Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "medical" sector.

Bristol Myers Squibb vs. Its Competitors

Bristol Myers Squibb (NYSE:BMY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Amgen has lower revenue, but higher earnings than Bristol Myers Squibb. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol Myers Squibb$48.30B2.01-$8.95B$2.6717.84
Amgen$33.42B4.77$4.09B$10.9627.08

Amgen has a net margin of 17.39% compared to Bristol Myers Squibb's net margin of 11.38%. Amgen's return on equity of 176.11% beat Bristol Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol Myers Squibb11.38% 87.62% 15.98%
Amgen 17.39%176.11%12.39%

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bristol Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.2%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Bristol Myers Squibb pays out 92.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb has raised its dividend for 17 consecutive years and Amgen has raised its dividend for 14 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb currently has a consensus price target of $58.00, indicating a potential upside of 21.75%. Amgen has a consensus price target of $307.82, indicating a potential upside of 3.71%. Given Bristol Myers Squibb's higher probable upside, research analysts clearly believe Bristol Myers Squibb is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol Myers Squibb
2 Sell rating(s)
13 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.32
Amgen
2 Sell rating(s)
12 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.35

In the previous week, Amgen had 16 more articles in the media than Bristol Myers Squibb. MarketBeat recorded 65 mentions for Amgen and 49 mentions for Bristol Myers Squibb. Amgen's average media sentiment score of 1.05 beat Bristol Myers Squibb's score of 0.98 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol Myers Squibb
34 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive
Amgen
47 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Positive

Bristol Myers Squibb has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Summary

Amgen beats Bristol Myers Squibb on 14 of the 20 factors compared between the two stocks.

Get Bristol Myers Squibb News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMY vs. The Competition

MetricBristol Myers SquibbMED IndustryMedical SectorNYSE Exchange
Market Cap$96.95B$2.90B$5.49B$20.51B
Dividend Yield5.36%2.69%5.38%3.76%
P/E Ratio17.8421.2626.2027.81
Price / Sales2.01279.34415.5037.44
Price / Cash7.8641.8936.4921.79
Price / Book5.907.508.054.55
Net Income-$8.95B-$55.05M$3.15B$984.47M
7 Day Performance1.95%2.49%1.92%3.57%
1 Month Performance-2.29%7.40%4.90%6.03%
1 Year Performance17.75%5.42%35.95%14.48%

Bristol Myers Squibb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMY
Bristol Myers Squibb
4.8953 of 5 stars
$47.64
+0.3%
$58.00
+21.7%
+15.0%$96.95B$48.30B17.8434,100
AMGN
Amgen
4.3262 of 5 stars
$277.23
+0.0%
$307.82
+11.0%
-6.6%$149.07B$33.42B25.2928,000Positive News
EXEL
Exelixis
4.7412 of 5 stars
$43.96
+0.7%
$43.56
-0.9%
+96.0%$11.99B$2.17B19.981,147Positive News
Analyst Forecast
Gap Up
GILD
Gilead Sciences
4.8387 of 5 stars
$110.44
-0.2%
$110.55
+0.1%
+62.8%$137.38B$28.74B23.2517,600Positive News
Insider Trade
MRNA
Moderna
4.3556 of 5 stars
$27.69
+2.0%
$46.61
+68.3%
-75.3%$10.71B$3.24B-3.175,800Trending News
Options Volume
Gap Up
VRTX
Vertex Pharmaceuticals
4.7168 of 5 stars
$445.60
+1.0%
$511.62
+14.8%
-4.1%$114.43B$11.02B-113.676,100Trending News
ABBV
AbbVie
4.9396 of 5 stars
$184.27
+1.1%
$211.29
+14.7%
+11.5%$325.49B$56.33B78.4155,000Trending News
JNJ
Johnson & Johnson
4.8459 of 5 stars
$151.59
-0.5%
$170.88
+12.7%
+6.4%$364.74B$88.82B16.86138,100Positive News
LLY
Eli Lilly and Company
4.9875 of 5 stars
$777.10
+0.2%
$1,011.61
+30.2%
-15.1%$736.49B$45.04B63.2347,000Positive News
MRK
Merck & Co., Inc.
4.9963 of 5 stars
$78.92
-0.2%
$109.19
+38.4%
-36.1%$198.17B$63.92B11.4975,000Positive News
PFE
Pfizer
4.8468 of 5 stars
$24.18
0.0%
$29.17
+20.6%
-11.3%$137.47B$63.63B17.5281,000Trending News
Dividend Announcement

Related Companies and Tools


This page (NYSE:BMY) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners